Seroprevalence rates of antibodies to phenolic glycolipid-I among school children as an indicator of leprosy endemicity.
In order to study whether the seroprevalence of antibodies to phenolic glycolipid-I (PGL-I) among school children is a useful indicator of the leprosy problem in certain areas, school surveys were carried out. These surveys have the advantage of targeting an easily accessible, stable and standardized population. Antibodies to the species-specific PGL-I of Mycobacterium leprae were detected in a simple gelatin particle agglutination test. We have determined the seroprevalence rates in 2835 school children from five different areas in three provinces of Sulawesi, Indonesia. Three areas with a case-detection rate of over 3.4/10,000 were designated as high-endemic areas. The other two were designated as low-endemic areas, having a case-detection rate of less than 1/10,000. The seroprevalence rates in the three high-endemic areas ranged from 26% to 28% (95% CI 21%-31%). In both low-endemic areas the seroprevalence rate was 7% (95% CI 5%-10%). In a second survey conducted in one high-endemic area 3 years after the first survey, the seroprevalence rate was the same as in the first survey. These results indicate that seropositivity rates among school children may reflect the leprosy incidence. They illustrate the potential applicability of seroprevalence as an indicator of the magnitude of the leprosy problem in a selected area.
van Beers
S
S
Department of Biomedical Research, Royal Tropical Institute, Amsterdam, The Netherlands.
Hatta
M
M
Klatser
P R
PR
D000907:Antibodies, Bacterial / Q000097:blood*; D000942:Antigens, Bacterial / Q000276:immunology; D002648:Child; D004359:Drug Therapy, Combination; D005260:Female; D006017:Glycolipids / Q000276:immunology*; D006801:Humans; D007075:Immunoglobulin M / Q000097:blood; D007214:Indonesia / Q000453:epidemiology; D007917:Leprostatic Agents / Q000627:therapeutic use; D007918:Leprosy / Q000097:blood / Q000188:drug therapy / Q000453:epidemiology*; D008297:Male; D009166:Mycobacterium leprae / Q000276:immunology* / Q000302:isolation & purification / Q000472:pathogenicity; D016036:Seroepidemiologic Studies
D000907:Antibodies, Bacterial; D000942:Antigens, Bacterial; D006017:Glycolipids; D007075:Immunoglobulin M; D007917:Leprostatic Agents; C045169:phenolic glycolipid I, Mycobacterium leprae